FirebrickPharma

28 August 2023

Ms Vanessa Nevjestic
Senior Adviser, Listings Compliance
Level 40 Central Park
152-158 St George's Terrace
PERTH WA 6000

Email: ListingsCompliancePerth@asx.com.au

Dear Vanessa

ASX PRICE QUERY

1. **Is FRE aware of any information concerning it that has not been announced to the market which, if known by some in the market, could explain the recent trading in its securities?**

   No. The Company is not aware of any information concerning it that has not been announced to the market which, if known by some in the market, could explain the recent trading in its securities.

2. **If the answer to question 1 is "yes".**
   (a) **Is FRE relying on Listing Rule 3.1A not to announce that information under Listing Rule 3.1? Please note that the recent trading in FRE's securities would suggest to ASX that such information may have ceased to be confidential and therefore FRE may no longer be able to rely on Listing Rule 3.1A. Accordingly, if the answer to this question is "yes", you need to contact us immediately to discuss the situation.**
   (b) **Can an announcement be made immediately? Please note, if the answer to this question is "no", you need to contact us immediately to discuss requesting a trading halt (see below).**
   (c) **If an announcement cannot be made immediately, why not and when is it expected that an announcement will be made?**

   The answer to question 1 is No – therefore not applicable.

3. **If the answer to question 1 is "no", is there any other explanation that FRE may have for the recent trading in its securities?**

   The Company announced on 9 August that its Phase 3 trial of Nasodine® Nasal Spray ("Nasodine") in the treatment for the common cold has successfully completed recruitment, with 500 subjects enrolled and that subject to availability of the complete efficacy data and timely completion of the statistical analysis, we expect to report headline results of the trial by the end of September.

4. **Please confirm that FRE is complying with the Listing Rules and, in particular, Listing Rule 3.1.**

   We confirm that the Company is in compliance with the Listing Rules and, in particular, Listing Rule 3.1.

5. **Please confirm that FRE's responses to the questions above have been authorised and approved under its published continuous disclosure policy or otherwise by its board or an officer of FRE with delegated authority from the board to respond to ASX on disclosure matters.**

   Confirmed.

Yours sincerely

Stephen Buckley
COMPANY SECRETARY

Authorised for release by Dr Peter Molloy, Executive Chairman & Chief Executive Officer

About Firebrick (ASX:FRE)

Firebrick is a pharmaceutical company founded in 2012 with the mission to develop and commercialise a nasal spray treatment for the common cold based around the potential of povidone-iodine as a broad-spectrum antimicrobial agent. The Company owns numerous granted and pending patents, including a core patent family that covers the use of intranasal povidone-iodine for the treatment and prevention of the common cold. Firebrick has conducted multiple human clinical trials on Nasodine and recently completed a second Phase 3 trial to confirm its efficacy as a treatment for the common cold and support international partnering and approvals.

Media enquiries:
Heidi Cuthbert
+61 411 272 366
heidi.cuthbert@multiplier.com.au

Investor enquiries:
Investors@firebrickpharma.com

28 August 2023

Reference: ODIN78847

Mr Stephen Buckley
Company Secretary
Firebrick Pharma Limited
PO Box 241
West Perth, Western Australia 6872

By email: sbuckley@governancecorp.com.au

Dear Mr Buckley

Firebrick Pharma Limited ('FRE'): Price and Volume - Query

ASX refers to the following:

A. The change in the price of FRE's securities from an intraday low of A$0.250 on 24 August 2023 to an intraday high of A$0.360 at the time of writing this letter today.

B. The significant increase in the volume of FRE's securities traded from 24 August 2023 to 28 August 2023.

Request for information

In light of this, ASX asks FRE to respond separately to each of the following questions and requests for information:

1. Is FRE aware of any information concerning it that has not been announced to the market which, if known by some in the market, could explain the recent trading in its securities?

2. If the answer to question 1 is "yes".

   (a) Is FRE relying on Listing Rule 3.1A not to announce that information under Listing Rule 3.1? Please note that the recent trading in FRE's securities would suggest to ASX that such information may have ceased to be confidential and therefore FRE may no longer be able to rely on Listing Rule 3.1A. Accordingly, if the answer to this question is "yes", you need to contact us immediately to discuss the situation.

   (b) Can an announcement be made immediately? Please note, if the answer to this question is "no", you need to contact us immediately to discuss requesting a trading halt (see below).

   (c) If an announcement cannot be made immediately, why not and when is it expected that an announcement will be made?

3. If the answer to question 1 is "no", is there any other explanation that FRE may have for the recent trading in its securities?

4. Please confirm that FRE is complying with the Listing Rules and, in particular, Listing Rule 3.1.

5. Please confirm that FRE's responses to the questions above have been authorised and approved under its published continuous disclosure policy or otherwise by its board or an officer of FRE with delegated authority from the board to respond to ASX on disclosure matters.

When and where to send your response

This request is made under Listing Rule 18.7. Your response is required as soon as reasonably possible and, in any event, by no later than **12:00 PM AWST Monday, 28 August 2023**. You should note that if the information requested by this letter is information required to be given to ASX under Listing Rule 3.1 and it does not fall within the exceptions mentioned in Listing Rule 3.1A, FRE's obligation is to disclose the information 'immediately'. This may require the information to be disclosed before the deadline set out in the previous paragraph and may require FRE to request a trading halt immediately.

Your response should be sent to me by e-mail at **ListingsCompliancePerth@asx.com.au**. It should not be sent directly to the ASX Market Announcements Office. This is to allow me to review your response to confirm that it is in a form appropriate for release to the market, before it is published on the ASX Market Announcements Platform.

Trading halt

If you are unable to respond to this letter by the time specified above, or if the answer to question 1 is "yes" and an announcement cannot be made immediately, you should discuss with us whether it is appropriate to request a trading halt in FRE's securities under Listing Rule 17.1. If you wish a trading halt, you must tell us:

- the reasons for the trading halt;
- how long you want the trading halt to last;
- the event you expect to happen that will end the trading halt;
- that you are not aware of any reason why the trading halt should not be granted; and
- any other information necessary to inform the market about the trading halt, or that we ask for.

We require the request for a trading halt to be in writing. The trading halt cannot extend past the commencement of normal trading on the second day after the day on which it is granted. You can find further information about trading halts in Guidance Note 16 *Trading Halts & Voluntary Suspensions*.

Suspension

If you are unable to respond to this letter by the time specified above, ASX will likely suspend trading in FRE's securities under Listing Rule 17.3.

Listing Rules 3.1 and 3.1A

In responding to this letter, you should have regard to FRE's obligations under Listing Rules 3.1 and 3.1A and also to Guidance Note 8 *Continuous Disclosure*: Listing Rules 3.1 – 3.1B. It should be noted that FRE's obligation to disclose information under Listing Rule 3.1 is not confined to, nor is it necessarily satisfied by, answering the questions set out in this letter.

Release of correspondence between ASX and entity

ASX reserves the right to release all or any part of this letter, your reply and any other related correspondence between us to the market under Listing Rule 18.7A.

Questions

If you have any questions in relation to the above, please do not hesitate to contact me.

Yours sincerely

Vanessa Nevjestic
Senior Adviser, Listings Compliance